Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.
about
Release of Doxorubicin by a Folate-Grafted, Chitosan-Coated Magnetic NanoparticleThe Pleiotropic Role of L1CAM in Tumor VasculatureThe stress polarity pathway: AMPK 'GIV'-es protection against metabolic insults.Vessel pruning or healing: endothelial metabolism as a novel target?Central Role of Metabolism in Endothelial Cell Function and Vascular Disease.Interaction of endothelial cells with macrophages-linking molecular and metabolic signaling.Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations.Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy.Metabolic Regulation of Angiogenesis in Diabetes and Aging.Tumor angiogenesis revisited: Regulators and clinical implications.Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer.Is There a Therapeutic Window for Metabolism-Based Cancer Therapies?Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond.Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism.A New Perspective on the Heterogeneity of Cancer Glycolysis.Therapeutic vaccines for high-risk HPV-associated diseases.How Endothelial Cells Adapt Their Metabolism to Form Vessels in Tumors.Tumor Microenvironment-Enabled Nanotherapy.De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors.Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis.Monocyte and macrophage immunometabolism in atherosclerosis.Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.Endothelial Cell Metabolism.Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy.COX‑2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression.Tumor vessel disintegration by maximum tolerable PFKFB3 blockade.A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.Energy metabolism in ALS: an underappreciated opportunity?Rediscovery in science-a second eureka moment? A case in the neovascularization in cancer.The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment.Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease.Angiogenic Factors produced by Hypoxic Cells are a leading driver of Anastomoses in Sprouting Angiogenesis-a computational study.The contributions of cancer cell metabolism to metastasisThe Warburg Effect in Endothelial Cells and its Potential as an Anti-angiogenic Target in CancerFructose 2,6-Bisphosphate in Cancer Cell MetabolismEndothelial Cell Metabolism in Atherosclerosis
P2860
Q33611961-6164CD3E-95C1-44BC-B765-14EC703AACA0Q37690651-4E5DF2B7-0C1A-4D36-8DB6-FEF7A5F9240AQ37715482-E987F87E-F7A5-472F-B14C-CBC2F18D8676Q39024164-98D21E5F-8668-4E02-8B23-C2C97ECEAA6DQ39137289-75B0C310-34C2-4071-BFA0-9EF198B74E3AQ39150057-9256740C-99AF-4ED3-B26F-F52BA3FE6595Q39232954-8A919C5A-4822-4791-A7D8-CADD2602E3C2Q39265746-F487D559-7955-4C95-94C0-5ED5D0C263B0Q39373990-5E7D66DC-C4DF-45F8-952C-7A697A77ACD3Q39393740-42F8513C-77DC-4103-A5AB-E284F9AFB368Q39406918-A234E3D0-4BCE-446C-950B-858015C396B9Q40971601-AD9DAE2C-E4A9-4CE8-94D5-5B78750BF458Q46291182-CD930819-F1D8-43EF-AB0C-743A813C8ACCQ47095437-17C525FD-B959-457C-B788-188F2A5B2F6CQ47208178-1B6E3EB7-03C0-4ACC-AF81-24558BFB7042Q47255618-5D9E6955-2290-4028-A4AF-1707C214BA88Q47363250-1E4DAAAB-ACAD-4D69-9B73-01D4FB7F2BCEQ47761233-9BFF4D26-112B-4236-8179-A720A8A480F0Q47822985-D6E56BE0-C83D-41F9-AAD6-EF5361CC6281Q48096055-1D0591B4-8815-46C3-9CD1-E3ABAEC4DB0EQ48265798-406F6699-01B5-4156-AD1C-8C4C1A612A20Q49679692-A831DC9B-2D1E-47D5-B0A9-ABB1781C1124Q49787990-48BD5B81-C55A-474C-85E6-94751B2F7E5DQ49923401-2B228280-0FDE-47D7-8787-6CBAA142D039Q50209286-28F34D7C-6095-4EC2-8B99-FA86DEBA8049Q50217994-5B050388-233A-4EA0-8FCA-E30458802AE2Q52603963-99AC141E-36EC-45C4-AB83-1D3926E19EDEQ52651163-C1F15645-166F-4FB9-B7EC-7B62334B5A45Q52668294-248FE3E0-DE87-4DDD-B113-9B2D8333F8E0Q55019858-B58B31DF-ECA8-4675-A3D9-FF33A9EED958Q55087013-B92B0823-C669-4539-ADFD-8A362536B9E6Q55280508-A208E310-C94E-408C-AB92-737E6A5B6720Q57188839-19C366AC-F996-4532-AB5B-1210B69A9EE0Q58750618-1095E9C5-6CAC-4CF4-9B76-37EA7E343B83Q58764753-7DBDA224-0CF7-4F6B-A9CC-30CC6BFA1AB8Q58797353-4ED216B9-4819-4BEC-8663-96620E210238
P2860
Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Inhibition of the Glycolytic A ...... is, and Improves Chemotherapy.
@en
type
label
Inhibition of the Glycolytic A ...... is, and Improves Chemotherapy.
@en
prefLabel
Inhibition of the Glycolytic A ...... is, and Improves Chemotherapy.
@en
P2093
P2860
P50
P1433
P1476
Inhibition of the Glycolytic A ...... sis, and Improves Chemotherapy
@en
P2093
Aleksandra Brajic
Andreas Pircher
Anna Kuchnio
Asrar B Malik
Bart Ghesquière
Bert Cruys
Bram Boeckx
Diether Lambrechts
Ilaria Decimo
P2860
P304
P356
10.1016/J.CCELL.2016.10.006
P50
P577
2016-11-17T00:00:00Z